KR101808398B1 - 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 - Google Patents

스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 Download PDF

Info

Publication number
KR101808398B1
KR101808398B1 KR1020157031951A KR20157031951A KR101808398B1 KR 101808398 B1 KR101808398 B1 KR 101808398B1 KR 1020157031951 A KR1020157031951 A KR 1020157031951A KR 20157031951 A KR20157031951 A KR 20157031951A KR 101808398 B1 KR101808398 B1 KR 101808398B1
Authority
KR
South Korea
Prior art keywords
clfa
protein
crm
staphylococcus aureus
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157031951A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129071A (ko
Inventor
라크쉬미 칸드케
아키히사 노노야마
타마라 샤퍼 핫쥐
샌딥 니마
Original Assignee
와이어쓰 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 엘엘씨 filed Critical 와이어쓰 엘엘씨
Publication of KR20150129071A publication Critical patent/KR20150129071A/ko
Application granted granted Critical
Publication of KR101808398B1 publication Critical patent/KR101808398B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
KR1020157031951A 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 Expired - Fee Related KR101808398B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22
US61/426,476 2010-12-22
PCT/IB2011/055883 WO2012085872A2 (en) 2010-12-22 2011-12-21 Stable immunogenic compositions of staphylococcus aureus antigens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137018851A Division KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Publications (2)

Publication Number Publication Date
KR20150129071A KR20150129071A (ko) 2015-11-18
KR101808398B1 true KR101808398B1 (ko) 2017-12-12

Family

ID=45444677

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157031951A Expired - Fee Related KR101808398B1 (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물
KR1020137018851A Ceased KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137018851A Ceased KR20130114210A (ko) 2010-12-22 2011-12-21 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물

Country Status (18)

Country Link
US (1) US20130259896A1 (OSRAM)
EP (2) EP2654784B1 (OSRAM)
JP (1) JP6097478B2 (OSRAM)
KR (2) KR101808398B1 (OSRAM)
CN (1) CN103826656B (OSRAM)
AU (1) AU2011346535B2 (OSRAM)
BR (1) BR112013016153A2 (OSRAM)
CA (1) CA2819120C (OSRAM)
DK (2) DK2654784T3 (OSRAM)
ES (2) ES2614815T3 (OSRAM)
HU (2) HUE047263T2 (OSRAM)
IL (1) IL226793B (OSRAM)
MX (1) MX350170B (OSRAM)
PL (2) PL3150222T3 (OSRAM)
PT (2) PT3150222T (OSRAM)
RU (1) RU2570730C2 (OSRAM)
SI (2) SI2654784T1 (OSRAM)
WO (1) WO2012085872A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298340B1 (en) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
PT3170508T (pt) * 2010-06-04 2020-01-16 Wyeth Llc Formulações de vacinas
CA2830415A1 (en) * 2011-03-16 2012-12-13 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3076998A1 (en) * 2013-12-04 2016-10-12 Glycovaxyn AG Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
CA2942122A1 (en) * 2014-04-10 2015-10-15 Asit Biotech S.A. Hsp-free allergen preparation
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
WO2020027466A1 (ko) 2018-07-28 2020-02-06 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR20220140500A (ko) * 2020-01-13 2022-10-18 압테보 리서치 앤드 디벨롭먼트 엘엘씨 약물 전달 시스템 성분에 대한 치료제 단백질의 흡착을 방지하기 위한 방법 및 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158334A1 (en) 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine
WO2006032472A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007113223A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008057550A2 (en) * 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1034277B1 (en) 1997-11-26 2012-06-27 Inhibitex, Inc. Extracellular matrix-binding proteins from Staphylococcus aureus
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
AU771426B2 (en) * 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
WO2001093905A1 (en) 2000-06-08 2001-12-13 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
WO2002102829A2 (en) 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
WO2004080490A2 (en) 2003-03-07 2004-09-23 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158334A1 (en) 2001-07-26 2005-07-21 Mario Contorni Vaccines comprising aluminium adjuvants and histidine
WO2006032472A2 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Immunogenic composition for use in vaccination against staphylococcei
WO2007113223A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2007113222A2 (en) * 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
WO2008057550A2 (en) * 2006-11-07 2008-05-15 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBO J. 21(24): 6660-6672(2002.12.16.)*
Vaccine 27(33): 4388-4401(2009.05.28.)*

Also Published As

Publication number Publication date
DK3150222T3 (da) 2020-01-27
CN103826656A (zh) 2014-05-28
IL226793B (en) 2019-02-28
WO2012085872A3 (en) 2012-08-30
PT2654784T (pt) 2017-02-13
EP2654784B1 (en) 2016-12-07
AU2011346535A1 (en) 2013-06-13
DK2654784T3 (en) 2017-02-13
EP3150222B1 (en) 2019-11-27
ES2614815T3 (es) 2017-06-02
MX2013006960A (es) 2013-07-15
HUE033072T2 (hu) 2017-11-28
SI3150222T1 (sl) 2020-02-28
BR112013016153A2 (pt) 2017-07-11
PT3150222T (pt) 2020-02-03
PL2654784T3 (pl) 2017-08-31
US20130259896A1 (en) 2013-10-03
CA2819120A1 (en) 2012-06-28
PL3150222T3 (pl) 2020-05-18
EP3150222A1 (en) 2017-04-05
HUE047263T2 (hu) 2020-04-28
CA2819120C (en) 2016-07-05
AU2011346535B2 (en) 2015-09-24
SI2654784T1 (sl) 2017-01-31
RU2013128277A (ru) 2015-01-27
MX350170B (es) 2017-08-28
EP2654784A2 (en) 2013-10-30
JP6097478B2 (ja) 2017-03-15
RU2570730C2 (ru) 2015-12-10
CN103826656B (zh) 2015-08-26
HK1197370A1 (en) 2015-01-16
JP2012136518A (ja) 2012-07-19
ES2769425T3 (es) 2020-06-25
KR20150129071A (ko) 2015-11-18
WO2012085872A2 (en) 2012-06-28
KR20130114210A (ko) 2013-10-16

Similar Documents

Publication Publication Date Title
DK2654784T3 (en) STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
KR101486122B1 (ko) 스타필로코커스 아우레우스 항원의 면역원성 조성물
JP6393804B2 (ja) 組成物および黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）血清型５および８莢膜多糖コンジュゲート免疫原性組成物を調製するための方法
RU2672053C2 (ru) Способ гликоконъюгации
US9561269B2 (en) Neisseria meningitidis compositions and methods thereof
US10829521B2 (en) Neisseria meningitidis composition and methods thereof
KR20130079536A (ko) 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
EP2461824A1 (en) Immunogenic composition comprising antigenic s. aureus proteins
HK1197370B (en) Stable immunogenic compositions of staphylococcus aureus antigens
HK1241717A1 (en) Immunogenic compositions of staphylococcus aureus antigens
HK1171653A (en) Immunogenic compositions of staphylococcus aureus antigens

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

FPAY Annual fee payment

Payment date: 20201005

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20210929

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20220921

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20231207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231207

St.27 status event code: N-4-6-H10-H13-oth-PC1903